Anvisa will discuss on April 29 a proposed regulation to govern the manipulation of GLP-1 medications, known as weight loss pens. The measure is part of an action plan announced on April 6 to control the market for these medications.
GLP-1 medications, known as weight-loss pens, include substances like semaglutide, tirzepatide and liraglutide and can currently only be acquired with retained medical prescriptions. The popularization of these medications has expanded the illegal market, including unauthorized compounded versions, raising concerns about health risks to the population.
Anvisa's board will discuss a proposed normative instruction on weight loss pens on April 29
The new regulation should define procedures for importation, supplier qualification, quality control, storage and transport
Anvisa created working groups with representatives from the Federal Councils of Pharmacy, Medicine and Dentistry
Covered by only some sources, or where the accounts diverge.
Covered by only some sources (1)
Anvisa published ordinances 488/2026 and 489/2026 creating the working groups
No gaps declared — all sources converge on the material facts.